ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

ESMO 2026 Insights | Professor Zhenyu Lin: Two Landmark Studies Led by Professors Tao Zhang and Kaixiong Tao’s Multidisciplinary Team at Wuhan Union Hospital Provide New Evidence from China for Precision Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Total neoadjuvant therapy (TNT) for locally advanced rectal cancer has become a major focus of research in recent years. A central unresolved question has been whether improvements in pathological complete response (pCR) rates can translate into meaningful survival benefits. At the same time, developing individualized neoadjuvant strategies for patients with different molecular subtypes based on biomarkers remains an urgent clinical priority.
ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

ESMO Oncology Update | Neoadjuvant Enfortumab Vedotin Plus Perioperative Durvalumab Significantly Improves EFS and OS in Patients with MIBC

The EV-303 and EV-304 studies have expanded the treatment landscape for muscle-invasive bladder cancer (MIBC) by incorporating perioperative enfortumab vedotin plus pembrolizumab into treatment strategies. At the 2026 European Society for Medical Oncology (ESMO) Congress, the phase III VOLGA study reported positive results. In patients with MIBC who were cisplatin-ineligible, neoadjuvant enfortumab vedotin plus perioperative durvalumab, with or without tremelimumab, significantly improved the primary endpoint of event-free survival (EFS) compared with radical cystectomy (RC) alone: median EFS was not reached versus 12.1 months (HR 0.51; 95% CI, 0.38–0.67; P<0.0001).
ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

ESMO Voices from China | Professor Xue Meng: 100% MPR Rate in the First Stage — Exploring a Chemotherapy-Free Neoadjuvant Approach to NSCLC with Sequential SBRT and Iparomlimab/Toripalimab

Platinum-based chemotherapy combined with immunotherapy has become an important perioperative treatment option for resectable non-small cell lung cancer (NSCLC). However, selecting an appropriate regimen remains challenging for patients who are unsuitable for platinum-based chemotherapy. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Xue Meng's team presented a phase II exploratory study investigating stereotactic body radiotherapy (SBRT) followed sequentially by iparomlimab/toviralimab (hereinafter referred to as the “Ipa-Tori combination antibody”), with continued immunotherapy after surgery. In the first-stage results, all nine patients achieved a major pathological response (MPR), representing an MPR rate of 100%. The pathological complete response (pCR) rate was 55.6% (5/9), and all patients underwent R0 resection. These findings provide preliminary support for further investigation, although validation in a larger patient population is needed. Oncology Frontier interviewed Professor Xue Meng about the study design, patient selection, and directions for further validation.
ESMO LBA Insights | The ADC Moment in Gynecologic Oncology: Professor Domenica Lorusso Discusses the TroFuse-005 Study

ESMO LBA Insights | The ADC Moment in Gynecologic Oncology: Professor Domenica Lorusso Discusses the TroFuse-005 Study

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. In the field of gynecologic oncology, one major study that attracted considerable attention was expected to reshape the treatment landscape for advanced endometrial cancer in the later-line setting. The randomized, open-label, global phase III TroFuse-005 study (ENGOT-en23/GOG-3095) demonstrated that the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (Sac-TMT) significantly improved progression-free survival (PFS) and overall survival (OS) compared with treatment of physician's choice (TPC) in patients with previously treated advanced or recurrent endometrial cancer. The objective response rate (ORR) was nearly doubled, making Sac-TMT the first TROP2 ADC in this patient population to demonstrate improvements in both OS and PFS compared with chemotherapy.
Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

At the 2026 European Society for Medical Oncology (ESMO) Congress, the Department of Urology at West China Hospital of Sichuan University reported interim results from the WUTSUP-02 study, which explored the value of neoadjuvant treatment with disitamab vedotin plus tislelizumab, followed by surgery and adjuvant tislelizumab, in patients with high-risk upper tract urothelial carcinoma (UTUC). Addressing the limited perioperative treatment options for this patient population, Professor Yige Bao of West China Hospital of Sichuan University discusses the rationale behind the WUTSUP-02 study, its interim efficacy findings, and future directions for patient selection and evidence generation.
ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

ESMO 2026 | ARROW Study Reanalysis Offers a Fresh Perspective on First-Line Benefits of Pralsetinib

RET fusions are rare oncogenic driver alterations in NSCLC. As the first RET inhibitor approved in China, pralsetinib has the ARROW study as a key foundation of its clinical evidence. A post hoc reanalysis presented at ESMO 2026 showed that first-line pralsetinib provides significant benefits in tumor shrinkage and disease control, while also improving tumor-related symptoms and supporting both efficacy and quality of life. Oncology Frontier invited Professor Yilong Wu from Guangdong Provincial People's Hospital to interpret the findings. He emphasized that results from single-arm studies should not be directly compared across trials and that baseline imbalances must be taken into account. These findings provide important evidence supporting first-line treatment of advanced RET fusion-positive NSCLC.
ESMO Expert Roundtable | First Global Phase III Success for TroFuse-005: Sacituzumab Tirumotecan Establishes a New Standard of Care for Previously Treated Advanced Endometrial Cancer

ESMO Expert Roundtable | First Global Phase III Success for TroFuse-005: Sacituzumab Tirumotecan Establishes a New Standard of Care for Previously Treated Advanced Endometrial Cancer

For a long time, patients with recurrent or metastatic endometrial cancer whose disease progresses after immunotherapy have had extremely limited benefit from chemotherapy, leaving them with few effective options in later lines of treatment. At the 2026 ESMO Congress, the Phase III TroFuse-005 study, presented as a late-breaking abstract (LBA), demonstrated that sacituzumab tirumotecan (Sac-TMT), a China-developed TROP2-targeted antibody-drug conjugate (ADC), significantly improved progression-free survival (PFS) and overall survival (OS) in this patient population.
ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

ESMO Voices from China | Professor Wenbin Li: Breaking Through the Blood–Brain Barrier — Novel Targeted Therapy and Chemotherapy Regimens Offer New Hope for Survival in Recurrent Glioma

Recurrent high-grade glioma (HGG) is associated with an extremely poor prognosis, particularly in patients with IDH-wildtype disease, whose median overall survival (OS) is only 6–10 months. Although targeted therapies have made progress, treatment of central nervous system (CNS) tumors remains extremely challenging because of the physiological barrier posed by the blood–brain barrier (BBB). At the 2026 European Society for Medical Oncology (ESMO) Congress, the team led by Professor Wenbin Li, Head of the Department of Neuro-Oncology at Beijing GoBroad Hospital, presented two research findings: an oral presentation of phase I data on the novel BRAF inhibitor HSK42360 in recurrent glioma, and large-scale prospective multicenter data on teniposide combined with platinum-based chemotherapy for recurrent HGG. On October 31, the 6th iHope Innovation Medicine Forum was held, focusing on the development of an Academic Research Organization (ARO) clinical research system and showcasing GoBroad Hospital's capabilities in building international multicenter clinical research networks and translating cutting-edge technologies into clinical practice. In this article, Professor Wenbin Li discusses breakthroughs in the clinical translation of innovative drugs and the evolving landscape of neuro-oncology treatment from the perspectives of translational medicine and clinical research.